Dong-A Faces Price Hit As Korea Ups Fight Against Illegal Rebates
Executive Summary
In its ongoing clamp down against illegal rebate activities in the domestic pharmaceutical industry, South Korea cuts prices of Dong-A ST’s drugs. This follows recent punitive measures against Novartis' Korean subsidiary.
You may also be interested in...
Korea Revises Rules To Curb Rebate Activities, Improve Ethics
South Korea continues efforts to root out illegal rebate payments for drugs and to step up the pharma industry's ethics and social responsibility by revising relevant rules, but in a way that doesn't harm patients' health.
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.
Korea 2017 Review: Biosimilar Advances, R&D Progress Restore Confidence
Strong global advances in biosimilars and progress in new drug development as well as clampdowns on illegal rebate payments have dominated headlines in South Korea in 2017.